Job Description
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Summary of Position:
As Country Medical Director, this person will be a strategic thought partner providing expert medical leadership and contributing to the development and execution of the Country launch strategy. This person will lead content development, KOL education programs, and support our cross-functional teams in Germany. As a key member of the European Medical team, reporting to EU Head of Medical Affairs, this person will be accountable for advancing Scholar Rock’s scientific leadership in Rare Neuromuscular Diseases including SMA and other pipeline indications. This person will thrive in this role if he/she is a self-starter and a highly collaborative individual who cares to have impact on patients in the rare disease space.
Scholar Rock is in the process of building its team in Germany, and the location of the future German headquarter is currently under evaluation, with Munich and Frankfurt being the leading options.